In 2023, the sold production of basic pharmaceutical products in France stood at a higher level than what we are projecting for the subsequent years. From the forecasted data, we observe a consistent decline in the value of sold production from 2024 to 2028. Specifically, the values drop significantly from 614.79 million euros in 2024 to 158.86 million euros by 2028. The year-on-year variations indicate considerable decreases: approximately 18.8% from 2024 to 2025, around 23.0% from 2025 to 2026, roughly 29.5% from 2026 to 2027, and about 41.4% from 2027 to 2028. This translates to a compound annual growth rate (CAGR) of about -22.0% over the next five years.

Future trends to watch for:

Potential impact of regulatory changes or governmental policies on the pharmaceutical industry.
Advancements in pharmaceutical technologies and their adoption rates.
Increased competition from emerging markets and how it may affect France's production.
Market dynamics influenced by health crises or shifts in global healthcare demands.